Somewhat Positive Press Coverage Somewhat Unlikely to Affect Ultragenyx Pharmaceutical (RARE) Stock Price

News coverage about Ultragenyx Pharmaceutical (NASDAQ:RARE) has trended somewhat positive recently, according to Accern. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ultragenyx Pharmaceutical earned a daily sentiment score of 0.24 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.246509020347 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the media headlines that may have effected Accern Sentiment’s scoring:

Ultragenyx Pharmaceutical (RARE) opened at 56.51 on Friday. Ultragenyx Pharmaceutical has a 12-month low of $51.67 and a 12-month high of $91.35. The company’s market cap is $2.40 billion. The stock’s 50 day moving average is $64.40 and its 200 day moving average is $66.83.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) EPS for the quarter, beating the consensus estimate of ($1.73) by $0.01. During the same quarter in the prior year, the business earned ($1.46) earnings per share. On average, equities analysts forecast that Ultragenyx Pharmaceutical will post ($7.24) earnings per share for the current year.

A number of equities research analysts have recently weighed in on the company. Jefferies Group LLC reaffirmed a “hold” rating and set a $68.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, July 14th. BidaskClub raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, June 20th. Canaccord Genuity reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Monday, May 8th. Stifel Nicolaus restated a “buy” rating and issued a $111.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 30th. Finally, Cowen and Company restated an “outperform” rating on shares of Ultragenyx Pharmaceutical in a research report on Thursday, June 29th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $83.50.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by BNB Daily and is the property of of BNB Daily. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at

In other Ultragenyx Pharmaceutical news, VP Theodore Alan Huizenga sold 480 shares of the business’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $57.46, for a total transaction of $27,580.80. Following the sale, the vice president now directly owns 9,366 shares of the company’s stock, valued at approximately $538,170.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 9.20% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply